Maintenance of remission in adult acute nonlymphoblastic leukemia using intermittent courses of cytosine arabinoside (NSC-63878) and 6-thioguanine (NSC-752).
Twenty adults (median age, 58 yrs) with acute nonlymphoblastic leukemia who had achieved complete remission were given maintenance therapy with monthly courses of cytosine arabinoside and 6-thioguanine, each in a dose of 100 mg/m2 every 12 hours for ten doses. The toxicity was minimal with no severe infections, bleeding, or treatment-related deaths. The treatment was often administered on an outpatient basis. The predicted life-table median remission duration is 14 months with 11 patients still in remission from 3+ to 29+ months.
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D003561:Cytarabine / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012075:Remission, Spontaneous; D013866:Thioguanine / Q000009:adverse effects / Q000627:therapeutic use*
D003561:Cytarabine; D013866:Thioguanine